Our Science

Publications 2017


Our scientific publications in high-quality journals reflect the quality of the innovative research in Entasis’ laboratories.

J. Lickliter, K. Lawrence, J. O’Donnell, and R. Isaacs
Safety and Pharmacokinetics (PK) in Humans of Intravenous ETX2514, a β-lactamase Inhibitor (BLI) which Broadly Inhibits Ambler Class A, C, and D β-lactamases
IDWeek 2017 conference in San Diego (2017)

Adam B. Shapiro, Ning Gao, Haris Jahić, Nicole M. Carter, April Chen, and Alita A. Miller.
Reversibility of Covalent, Broad-Spectrum Serine β-Lactamase Inhibition by the Diazabicyclooctenone ETX2514
ACS Infectious Diseases (2017)

Durand-Réville T, et al
ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii
Nature Microbiology (2017)

Iyer R, Sylvester M, Velez-Vega C, Tommasi R, Durand-Réville T, Miller A*
Whole-Cell-Based Assay To Evaluate Structure Permeation Relationships for Carbapenem Passage through the Pseudomonas aeruginosa Porin OprD
ACS Infectious Diseases (2017)



“Our scientific approach and expertise, coupled with Entasis’ strong pipeline of programs, really make us stand out in the field of antibacterial drug discovery and development.”

— Satenig Guler, Senior Scientist